Copper load
GHK-Cu is about 16% copper by weight, so a 50 mg vial contains roughly 8 mg of elemental copper. Spread over four weeks, that is not high relative to the adult oral copper upper limit of 10 mg daily. But injected copper bypasses the gut, which is where the body regulates copper absorption.
No human study has measured what subcutaneous copper peptide injections do to copper levels over weeks. A 2016 cell study found GHK-Cu produced fewer toxicity markers than copper salts in skin cells at the same copper concentration, which says something about the chelate but nothing about a month of injections. That is unknown, and it is concerning.
TB-500 and angiogenesis
TB-500 promotes new blood vessel formation, which is its mechanism of action and the reason it is unsuitable for anyone with active or suspected cancer. Thymosin beta-4 is elevated in preclinical models of several cancer types, though causality is unclear. In the blend, it is indispensable.
BPC-157
Community reports describe injection site reactions, occasional nausea, headache, and dizziness at high doses. With only two human subjects, there is no controlled human trial data.
Interactions no one has tested
GHK-Cu contains copper and is pro-angiogenic. TB-500 is also pro-angiogenic. BPC-157 raises VEGF and nitric oxide. One syringe contains three pro-angiogenic signals, which may explain why the blend “works” for tendons and is also the reason for caution in anyone with a cancer history.
Both explanations may be true, and neither has been measured. An animal study combining two of the three found no benefit over TB-500 alone, which at least suggests synergy is not guaranteed.
Product quality
A single-peptide vial needs identity testing against one expected mass. A three-peptide vial requires confirming three identities and measuring three contents, and even a certificate of analysis stating “99%” purity says almost nothing about whether the labeled ratio matches the powder. This is not a theoretical concern in 2026: on July 30, the founder of Paradigm Peptides was sentenced to 70 months in federal prison for falsifying certificates of analysis and selling products that did not match their labels. On June 17, the FDA sent a warning letter to a supplier called Wholesale Peptide for selling injectable peptides as unapproved drugs.
Who should not use it
Anyone with active or suspected cancer, due to TB-500; anyone pregnant or breastfeeding, due to lack of safety data for any component; anyone with Wilson’s disease or other copper metabolism disorders, due to GHK-Cu; and any tested athlete, because two of the three components are banned.
Conclusion
GLOW safety has three unknowns: injected copper load, TB-500’s angiogenesis risk, and three pro-angiogenic signals never tested together. Understanding these risks matters more than believing in “synergy.”